Anticancer research最新文献

{"title":"Contrasting Role of COMMD5 in Renal Cell Carcinoma: Tumor Suppression and Metastatic Enhancement.","authors":"Hiroyuki Matsuda, Jin Ikeda, Maiko Ogasawara-Nosoko, Morito Endo, Pavel Hamet, Johanne Tremblay","doi":"10.21873/anticanres.17523","DOIUrl":"https://doi.org/10.21873/anticanres.17523","url":null,"abstract":"<p><strong>Background/aim: </strong>Despite diagnostic and therapeutic advances, renal cell carcinoma (RCC) metastasis remains difficult to eliminate. Copper metabolism MURR1 domain-containing 5 (COMMD5), a protein involved in tubular epithelial integrity, is implicated in RCC tumorigenesis. This study explored its role in RCC metastasis.</p><p><strong>Materials and methods: </strong>Proliferation, adhesion, and survival under hypoxia in RCC cells over-expressing COMMD5 were evaluated. A murine model was used to evaluate metastatic potential <i>in vivo</i>. Clinical data were analyzed for correlations between COMMD5 expression and patient outcomes.</p><p><strong>Results: </strong>COMMD5 over-expression facilitated cancer cell differentiation and suppressed proliferation but enhanced adhesion and survival under hypoxia. <i>In vivo</i>, it reduced metastatic lung nodule growth but increased the number of metastatic lung nodules. Clinically, high COMMD5 expression in normal kidneys correlated with smaller RCC size, while high COMMD5 expression in tumors was linked to poor metastasis-free survival.</p><p><strong>Conclusion: </strong>COMMD5 plays dual roles in RCC progression, as a tumor suppressor and a metastasis enhancer.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1373-1385"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mid-term Combination Immunotherapy and its Effect on the Albumin-Bilirubin Score in Unresectable Hepatocellular Carcinoma.","authors":"Akifumi Kuwano, Masayoshi Yada, Kosuke Tanaka, Junro Takahira, Hideo Suzuki, Kenta Motomura","doi":"10.21873/anticanres.17552","DOIUrl":"https://doi.org/10.21873/anticanres.17552","url":null,"abstract":"<p><strong>Background/aim: </strong>Combination immunotherapy has emerged as a standard approach for systemic chemotherapy in unresectable hepatocellular carcinoma (HCC). Preservation of liver function is crucial for prolonging survival during treatment. However, real-world data on liver function dynamics during combination immunotherapy remain limited. This study evaluated the mid-term impact of combination immunotherapy on liver function using the albumin-bilirubin (ALBI) score.</p><p><strong>Patients and methods: </strong>Patients receiving durvalumab plus tremelimumab (Dur/Tre group, n=13) or atezolizumab plus bevacizumab (Atez/Bev group, n=35) for at least six months were retrospectively analyzed. ALBI scores were assessed at the start of treatment (SOT), three months, and six months of treatment.</p><p><strong>Results: </strong>In the Dur/Tre group, median (interquartile range) ALBI scores at SOT, three months, and six months of treatment were -2.09 (-2.39 to -1.78), -2.42 (-2.63 to -2.16), and -2.48 (-2.69 to -2.40), respectively, demonstrating a significant improvement at six months compared with SOT (<i>p</i>=0.002). In contrast, the Atez/Bev group exhibited ALBI scores of -2.44 (-2.73 to -2.14), -2.44 (-2.56 to -2.02), and -2.36 (-2.57 to -1.78), indicating significant deterioration at six months of treatment (<i>p</i>=0.010). Among patients with proteinuria, ALBI scores remained unchanged (<i>p</i>=0.171), whereas those without proteinuria experienced significant worsening (<i>p</i>=0.030). In both univariate and multivariate analyses, Dur/Tre treatment [hazard ratio (HR)= 0.022; <i>p</i>=0.005] and objective response rate (HR=0.091; <i>p</i>=0.031) were independently associated with reduced ALBI score deterioration.</p><p><strong>Conclusion: </strong>Dur/Tre therapy may better preserve liver function compared with Atez/Bev therapy in patients with unresectable HCC.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1713-1721"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant Chemoradiotherapy Enhances Tumor PD-L1 Expression in Pancreatic Cancer.","authors":"Kanechika DEN, Takashi Murakami, Ryusei Matsuyama, Kentaro Miyake, Yuki Homma, Yasuhiro Yabushita, Ryutaro Mori, Yukihiko Hiroshima, Ikuma Kato, Itaru Endo","doi":"10.21873/anticanres.17554","DOIUrl":"https://doi.org/10.21873/anticanres.17554","url":null,"abstract":"<p><strong>Background/aim: </strong>Programmed cell death-1 (PD-1) and its ligand PD-L1 play crucial roles in cancer-related immunosuppression. Previous reports have hinted at the potential of neoadjuvant chemoradiotherapy (NACRT) to shift the immunosuppressive microenvironment of pancreatic adenocarcinoma (PDAC) toward an immunogenic state in selected patients. This study aimed to assess the effects of NACRT on PD-L1 expression and PD-1⁺ lymphocyte infiltration in PDAC.</p><p><strong>Patients and methods: </strong>Eighty-two patients with PDAC underwent surgical resection. Among them, 55 patients with borderline-resectable PDAC (BR-PDAC) received NACRT, while 27 patients with resectable PDAC underwent straightforward resection without NACRT. Using immunohistochemical staining, resected specimens were examined to assess PD-1⁺ tumor-infiltrating lymphocytes (TILs), CD8⁺ TIL, forkhead box P3 positive (Foxp3⁺) TILs, and PD-L1 expression in tumor cells.</p><p><strong>Results: </strong>High PD-L1 expression correlated positively with NACRT treatment and inversely with PD-1⁺ TILs. A high CD8⁺ TILs level was strongly correlated to PD-L1 expression. The numbers of PD-1⁺ TILs and Foxp3⁺ TILs were significantly correlated in the straight-line group but not in the NACRT group. In both groups, no significant correlation was found between the overall survival of patients and PD-1⁺ TILs or PD-L1 expression alone.</p><p><strong>Conclusion: </strong>NACRT in pancreatic cancer may affect TILs and PD-L1 expression, thereby improving the immunosuppressive microenvironment and implying a potential synergy between checkpoint inhibitors and radiation treatment.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1731-1747"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Huge Hepatocellular Carcinoma With Major Arteriovenous Shunt Successfully Treated With Chemoembolization Plus Lenvatinib Therapy Followed by Radiotherapy.","authors":"Toshiro Masuda, Toru Beppu, Hideaki Miyamoto, Yasunori Nagayama, Yoshiyuki Fukugawa, Toshihiko Motohara, Yuki Adachi, Eri Oda, Ryuichi Karashima, Kazuaki Yoshizato, Takatoshi Ishiko","doi":"10.21873/anticanres.17558","DOIUrl":"https://doi.org/10.21873/anticanres.17558","url":null,"abstract":"<p><strong>Background/aim: </strong>Large hepatocellular carcinoma (HCC) (defined as ≥10 cm) is associated with a poor prognosis in both resectable and unresectable patients. Liver resection and multidisciplinary treatment are recommended for solitary huge and multiple huge HCCs, respectively.</p><p><strong>Case report: </strong>The patient presented with a hypervascular HCC measuring over 10 cm in the right liver lobe and a suspected hypovascular tumor in the medial segment. He had nonB-nonC hepatitis with metabolic disease together with untreated 3-vessel coronary artery disease. Transarterial chemoembolization (TACE) and lenvatinib treatment were performed in parallel with coronary stent treatment. The treatment for HCC was effective, with the tumor's contrast enhancement almost completely disappearing and the protein induced by the absence of vitamin K or antagonist-II level decreasing from 91,616 mAU/ml to 152 mAU/ml. After portal vein embolization, the tumor became resectable; however, the patient did not consent to a major hepatectomy. Only contrast-enhanced ultrasonography showed viable tumor tissue near the hepatic hilar Glissonean capsule. These tumors were contraindicated for thermal ablation; therefore, intensity-modulated radiation therapy (30 Gy/10 fractions) was performed. Percutaneous microwave ablation was successfully applied to another growing HCC in the medial segment. Three years after the initial treatment, the patient remains well and free of disease.</p><p><strong>Conclusion: </strong>For patients who are contraindicative for immune checkpoint inhibitors or major liver resection, TACE plus lenvatinib followed by radiotherapy is safe and potentially an optimal treatment option.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1785-1792"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant Treatment for Resectable Pancreatic Cancer.","authors":"Toru Aoyama, Kentaro Hara, Aya Saito, Haruhiko Cho","doi":"10.21873/anticanres.17519","DOIUrl":"https://doi.org/10.21873/anticanres.17519","url":null,"abstract":"<p><p>Pancreatic cancer is the seventh leading cause of cancer-related death worldwide. Surgical resection, such as pancreatoduodenectomy or distal pancreatectomy, is the standard curative treatment for resectable pancreatic cancer. So far, several studies suggested that management of micro metastasis is one of the approaches to improve pancreatic cancer patients. The use of chemotherapy or chemo radiation therapy during perioperative periods is most promising adjuvant treatment. To introduce the adjuvant treatment during perioperative periods for pancreatic cancer, it is necessary to establish the optimal methods, regimen, and timing of adjuvant treatment. To date, many randomized trials have been conducted to examine the efficacy of adjuvant therapies. Since 2000, different evidence has emerged for postoperative adjuvant chemoradiation, postoperative adjuvant chemotherapy, and perioperative adjuvant chemotherapy for resectable pancreatic cancer. This review summarizes the background, current status, and future perspectives of adjuvant therapy for resectable pancreatic cancer.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1329-1341"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of Outcomes for Patients With Advanced Renal Cell Carcinoma: Immuno-Oncology Era <i>Versus</i> Tyrosine Kinase Inhibitor Era in the IMDC Favorable-risk Group.","authors":"Hiroki Ishihara, Yuki Nemoto, Shinsuke Mizoguchi, Koichi Nishimura, Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Junpei Iizuka, Tsunenori Kondo, Toshio Takagi","doi":"10.21873/anticanres.17545","DOIUrl":"https://doi.org/10.21873/anticanres.17545","url":null,"abstract":"<p><strong>Background/aim: </strong>Scarce data are available on the changes in outcomes related to advanced renal cell carcinoma (RCC), from the previous tyrosine kinase inhibitor (TKI) era to the current immuno-oncology (IO) era, among patients in the IMDC favorable-risk group.</p><p><strong>Patients and methods: </strong>Among 618 patients with previously untreated advanced RCC according to our database, 72 classified with an International Metastatic RCC Database Consortium (IMDC) favorable risk were selected. These patients were divided into two groups (IO and TKI eras) based on the treatments recognized as the standard of care at the time of their treatment. We compared the effectiveness and safety profiles according to the treatment era.</p><p><strong>Results: </strong>Out of 72 patients, 31 (43%) were treated in the IO era and 41 (57%) in the TKI era. No significant differences were found in patient backgrounds (<i>p</i>>0.05). Progression-free survival (median: 23.0 <i>vs</i>. 29.3 months, <i>p</i>=0.547) and overall survival (median: not reached <i>vs</i>. 114.7 months, <i>p</i>=0.785) showed no significant difference between the two eras. The objective response rate was higher in the IO era (84% <i>vs</i>. 41%, <i>p</i>=0.0003), and the treatment era was an independent predictor of an objective response (odds ratio=0.14, <i>p</i>=0.0006). The rates of treatment interruption (65% <i>vs</i>. 46%, <i>p</i>=0.155) and discontinuation (32% <i>vs</i>. 22%, <i>p</i>=0.420) did not significantly differ between eras.</p><p><strong>Conclusion: </strong>The implementation of IO therapies has enhanced tumor response rates among patients within the IMDC favorable-risk group, although extended follow-up is necessary to ascertain any survival benefits.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1643-1652"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overall Incidence of Postoperative Pancreatic Fistula After Early Drain Removal in Distal Pancreatectomy.","authors":"Teruhisa Sakamoto, Jun Yoshida, Mikiya Kishino, Yuki Murakami, Kozo Miyatani, Yuji Shishido, Kyoichi Kihara, Manabu Yamamoto, Tomoyuki Matsunaga, Naruo Tokuyasu, Yoshiyuki Fujiwara","doi":"10.21873/anticanres.17553","DOIUrl":"https://doi.org/10.21873/anticanres.17553","url":null,"abstract":"<p><strong>Background/aim: </strong>Detailed evaluation of the overall incidence of postoperative pancreatic fistula (POPF) after early drain removal (EDR) in distal pancreatectomy (DP) is lacking. This study aimed to assess postoperative complications, including the overall incidence of POPF, with EDR following DP.</p><p><strong>Patients and methods: </strong>Ninety-nine patients who underwent EDR after DP regardless of drain fluid amylase level between January 2017 and December 2024 were enrolled in this study. Data were retrospectively analyzed to evaluate complications, including the overall incidence of POPF.</p><p><strong>Results: </strong>The overall incidence of POPF after EDR was 31.3% (31/99 patients), of which the incidence of clinically relevant POPF requiring reinsertion of abdominal drains was 4.0% (4/99 patients). The incidence of Clavien-Dindo grade ≤ II POPF was high, at 27.3% (27/99 patients). There were no complications of Clavien-Dindo grade IV or V. Univariate analysis of pre- and intraoperative variables showed that injury to the pancreatic parenchyma near the pancreatic stump was the only risk factor for drain reinsertion after EDR.</p><p><strong>Conclusion: </strong>EDR, regardless of drain fluid amylase level, reduces the incidence of Clavien-Dindo grade ≥ IIIa POPF after DP. However, EDR does not necessarily contribute to a decrease in the overall incidence of POPF after DP.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1723-1730"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Programmed Cell Death 10 (<i>PDCD10</i>) Is a Candidate Tumor-associated Gene in Esophageal Squamous Cell Carcinoma.","authors":"Yoshiki Hiraki, Takaaki Masuda, Yushi Motomura, Taro Tobo, Hideyuki Saito, Kosuke Hirose, Takashi Ofuchi, Yasuo Tsuda, Hajime Otsu, Yusuke Yonemura, Satohiro Kai, Masakazu Hirakawa, Kousei Ishigami, Koshi Mimori","doi":"10.21873/anticanres.17527","DOIUrl":"https://doi.org/10.21873/anticanres.17527","url":null,"abstract":"<p><strong>Background/aim: </strong>Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor survival rates. Effective molecular-targeted therapies are urgently needed. This study aimed to identify novel candidate tumor-associated genes in ESCC by analyzing chromosomal amplification regions.</p><p><strong>Materials and methods: </strong>DNA copy number variation (CNV) and mRNA expression data were obtained from The Cancer Genome Atlas (TCGA) and Cancer Cell Line Encyclopedia (CCLE). Single-cell RNA sequencing data from Gene Expression Omnibus (GEO) were analyzed using Scanpy. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded (FFPE) ESCC tissues. <i>PDCD10</i> was identified as a potential tumor-associated gene, and its association with clinicopathological factors and prognostic impact was evaluated using Kaplan-Meier survival and Cox regression analyses. Pathway analysis was performed to investigate the biological processes, and drug sensitivity profiling was conducted to identify compounds whose efficacy correlated with <i>PDCD10</i> expression in ESCC cell lines.</p><p><strong>Results: </strong><i>PDCD10</i>, a signaling protein involved in cell proliferation and vascular development, showed significant amplification and over-expression in ESCC cases. High <i>PDCD10</i> expression was associated with poor prognosis. Single-cell RNA sequencing confirmed its tumor-specific expression. GSEA revealed enrichment of mTORC1 signaling, E2F, and Myc target pathways in high <i>PDCD10</i>-expressing tumors. Drug sensitivity analysis identified Azelaic acid and Rebamipide as compounds whose efficacy correlated with <i>PDCD10</i> expression in ESCC cell lines.</p><p><strong>Conclusion: </strong><i>PDCD10</i> could be a novel tumor-associated gene associated with tumor progression and poor prognosis in ESCC. Azelaic acid and Rebamipide are candidate therapeutic agents targeting <i>PDCD10</i>.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1419-1433"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Postoperative Outcomes of Laparoscopic <i>Versus</i> Open Gastrectomy in Older Patients With Gastric Cancer.","authors":"Tomohiro Takahashi, Tomoyuki Matsunaga, Hiroaki Saito, Tomohiro Osaki, Sadamu Takahashi, Akemi Iwamoto, Kenji Fukuda, Kenjiro Taniguchi, Hirohiko Kuroda, Tsutomu Takeuchi, Kenji Sugamura, Kenichi Sumi, Kuniyuki Katano, Shota Shimizu, Yuji Shishido, Kozo Miyatani, Teruhisa Sakamoto, Yoshiyuki Fujiwara","doi":"10.21873/anticanres.17548","DOIUrl":"https://doi.org/10.21873/anticanres.17548","url":null,"abstract":"<p><strong>Background/aim: </strong>Several studies have investigated the safety of laparoscopic gastrectomy (LG) for gastric cancer (GC). However, many of these studies excluded older patients, and few multicenter studies have compared LG and open gastrectomy (OG) in older patients with GC. We compared the postoperative short- and long-term outcomes of LG and OG in >75 years old patients with GC in a multicenter study.</p><p><strong>Patients and methods: </strong>The study included 926 patients aged >75 years who underwent gastrectomy from January 2003 to December 2017 at 12 regional hospitals. After propensity score-matching (PSM), the two surgical groups' short- and long-term outcomes were analyzed. PSM was applied for variables such as sex, depth of tumor invasion, lymph node metastasis, histologic type, pathological stage, gastrectomy, and lymph node dissection.</p><p><strong>Results: </strong>After 1:1 matching, 258 cases in each group were analyzed. The LG group showed significantly longer surgery times and reduced blood loss (<i>p</i><0.001). There were no significant differences in the incidence of postoperative complications graded Clavien-Dindo ≥ II between the groups (23.6% <i>vs</i>. 19.4%, <i>p</i>=0.239). However, the LG group had lower and higher incidences of pneumonia (1.9% <i>vs</i>. 5.4%, <i>p</i>=0.035) and pancreatic fistula (PF; 4.7% <i>vs</i>. 0.04%, <i>p</i>=0.003), respectively. The two groups had no significant overall and disease-specific survival differences across all stages.</p><p><strong>Conclusion: </strong>In patients aged >75 years with GC, LG can be a viable approach with careful clinical management for the risk of PF, without compromising long-term survival.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1667-1679"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Splenic Angiosarcoma and Numerous Liver Metastases Presenting the Kasabach-Merritt Phenomenon.","authors":"Toshiro Masuda, Toru Beppu, Yasunori Nagayama, Hideaki Miyamoto, Yoshihiro Komohara, Eri Oda, Ryuichi Karashima, Takashi Nakagaki, Yuki Adachi, Takatoshi Ishiko","doi":"10.21873/anticanres.17557","DOIUrl":"https://doi.org/10.21873/anticanres.17557","url":null,"abstract":"<p><strong>Background/aim: </strong>Splenic angiosarcoma is a rare and serious malignancy. We investigated the diagnosis and the suitable treatment strategy for metastatic splenic angiosarcoma with the Kasabach-Merritt phenomenon.</p><p><strong>Case report: </strong>A 76-year-old man was referred because of abdominal discomfort together with anemia, thrombocytopenia, and disseminated intravascular coagulopathy. Contrast-enhanced computed tomography revealed some huge, low-attenuation large splenic tumors and numerous liver tumors. Magnetic resonance imaging showed tumors with low and heterogeneous high signal intensity on T1-weighted and T2-weighted images, respectively. Several splenic tumors contained peripheral hypointense areas on T2WI that demonstrated a signal drop in in-phase compared to opposed-phase chemical-shift T1WI. A percutaneous needle biopsy of liver tumors with needle-tract radiofrequency ablation was performed without bleeding. The patient was pathologically diagnosed as splenic angiosarcoma by several immunohistochemical analyses. We started anticoagulant-fibrinolytic therapy with nafamostat mesylate; however, partial ischemia of the jejunum happened twice, and partial resections and the creation of an ileostomy were performed. The patient has been relatively stable for 3 months with paclitaxel monotherapy followed by oral pazopanib. Kasabach-Merritt phenomenon has been stable during good control of splenic angiosarcoma.</p><p><strong>Conclusion: </strong>Metastatic splenic angiosarcoma with the Kasabach-Merritt phenomenon might be controlled by accurate diagnosis, precise surgical intervention for digestive organ ischemia, and effective chemotherapy. The Kasabach-Merritt phenomenon is an effective indicator of chemotherapy response. Furthermore, the development and clinical application of new chemotherapies are needed.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1777-1784"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}